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Summary. Venous thrombosis of the upper extremity is a rare
disease. Therefore, not as much is known about risk factors,
treatment and the risk of recurrence as for venous thrombosis of
the leg.Only central venous catheters and strenuous exercise are
commonly known risk factors for an upper extremity venous
thrombosis. In this review an overview of the different risk
factors, possible treatments and the complications for patients
with a venous thrombosis of the upper extremity is given.
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Introduction
Venous thrombosis of the upper extremity (UEDVT), defined
as a thrombus in the subclavian, axillary or brachial vein,
accounts for 4–10% of all venous thromboses [1–6]. This figure
may be an underestimation given that UEDVT is often
asymptomatic [7–9]. The low incidence of UEDVT compared
with the leg may be explained by the lower gravitational stress.
Additionally, the veins of the upper extremities contain fewer
valves than the legs, which could be potential foci for thrombus
formation. Furthermore, stasis contributing to the occurrence
of thrombosis is very rare in the upper extremity. The most
likely conditions for stasis to occur are surgery and plaster cast
of the upper extremity [7,10].
Primary venous thrombosis
UEDVT is usually divided into primary and secondary
thrombosis [4,11]. PrimaryUEDVT includes idiopathic throm-
bosis and thrombosis associated with the thoracic outlet
syndrome or effort (Paget–Schro¨tter syndrome) [12,13]. The
incidence of primary UEDVT is 2 per 100 000 person years
[2,14] and accounts for approximately 30% of all UED-
VT[4,14,15].
Thoracic outlet syndrome (TOS) relates to various forms of
compression in the thoracic outlet. The thoracic outlet is
located between the base of the neck and the axilla. Compres-
sion of the thoracic outlet can either be on the brachial plexus
or on the blood vessels in the outlet. Compression of both
nerves and vessels is rare. In approximately 3–10%of the cases,
TOS will be vascular, which can be divided into venous or
arterial TOS [16]. UEDVT can be caused by venous TOS. In
venous TOS the thoracic outlet veins are compressed by the
clavicle and the first rib [17]. This will result in compression or
sudden occlusion of the vein. Approximately 60% of patients
with primary UEDVT have the thoracic outlet syndrome [4].
Treatment consists of either anticoagulation alone or in
combination with resection of the first rib [17,18].
Paget–Schro¨tter syndrome, also called effort thrombosis, is a
manifestation of TOS. The syndrome mostly occurs in young
healthy persons, related to strenuous activity of the arm during
sports [19–23]. The effort causes microtrauma of the vessel
intima by repeated compression of the clavicle and first rib,
which activates the coagulation [2]. The compression is mostly
caused by trauma or by the enlarged muscles in the shoulder
girdle [4,16,18,20,24–26].
Secondary venous thrombosis
Secondary UEDVT is thrombosis with a known risk factor.
These risk factors can be genetic or acquired [11,27,28].
Central venous catheters
The main risk factor for UEDVT is a central venous
catheter(CVC) [6,27]. The catheters are used to provide
chemotherapy, medication and parenteral nutrition, and for
administration of fluids, blood products and hemodialysis [9].
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Several studies have investigated the incidence and risk factors
for UEDVT in patients with a CVC, as well as prophylaxis to
prevent thrombosis [29–37].
CVCs can be divided into peripherally inserted catheters,
chest catheters and pacemakers. Peripherally inserted catheters
have an incidence of thrombosis from 10% to 38% [29,30,37].
The incidence of UEDVT for chest catheters ranges from 2%
to 41% [31,32,35,37]. The risk of thrombosis is dependent on
the diameter of the catheter; a larger diameter gives a higher
risk of thrombosis [30]. The risk of UEDVT is lower for
polyurethane and silicone catheters compared with poly-
ethylene or Teflon-coated catheters [38,39].
Pacemakers give thrombosis in 10%. This risk increases with
the number of leads from the pacemaker [40,41]. Most
occlusions occur within the first 2 months after insertion of
the catheter [30,42,43].
Malignancy
Malignancy is an important risk factor for UEDVT. However,
the increased risk in patients withmalignancy is mainly induced
by CVCs [27,44,45]. In the Multiple Environmental and
Genetic Assessment (MEGA) study of risk factors for venous
thrombosis, a population-based case control study, 179
patients with UEDVT were compared with 2399 control
subjects. In patients without a CVC with an active form of
malignancy an 18-fold increased risk of UEDVT compared
with patients without active malignancy was found. Active
malignancy was defined as malignancy diagnosed 5 years or
less before first venous thrombosis [27]. A 7.7-fold increased
risk of UEDVT was found when all, active and inactive,
malignancies were included.
Coagulation abnormalities and genetic risk factors
In the literature the prevalence of coagulation abnormalities in
patients with UEDVT ranges from 8% to 61% [1,28,46–48].
The differences can be explained by the size of these studies,
including only between 18 and 51 patients. Additionally, the
studies had different time points of blood collection: at
diagnosis of thrombosis, 3 weeks after the event or after
discontinuation of anticoagulation therapy. This can influence
the assessment of coagulation abnormalities. Only anti-
phospolipid antibodies seem consistently more frequently
present compared with the healthy population [46–48].
Factor (F) V Leiden [49] and the prothrombin 20210A [50]
mutation are common genetic risk factors in venous thrombo-
sis of the leg, and may be a risk factor for UEDVT. Some
studies reported an increased risk for either factor V Leiden or
the prothrombin 20210A mutation or both. An Italian study
included 115 patients with an UEDVT and 797 control
subjects. A 5- to 6-fold increased risk of UEDVTwas found for
patients with one of themutations [51]. In a Spanish study of 79
cases and 165 controls an increased risk was found for patients
with the prothrombin 20210A mutation, and no effect was
found for the FV Leiden mutation [11]. A follow-up study
including 257 patients with a CVC found a 3-fold increased risk
of a UEDVT in patients with a mutation compared with
patients without a mutation [34]. Although the majority of the
other studies showed an increased risk for patients with the FV
Leiden or prothrombin 20210A mutation, the number of
patients in these studies was small. Therefore, no solid
conclusions can be drawn.
Oral contraceptive use, surgery and plaster cast
Oral contraceptive use did not increase the risk of UEDVT in
most studies [4,46,51,52]. However, in a Spanish study a 5.7-
fold (CI 2.1–15.7) increased risk was found, and the MEGA
study found a 2-fold (CI 1.1–3.8) increased risk [11,27]. So,
there is no consensus about oral contraceptive use as risk factor
for UEDVT. Differences may be explained by the type of
patients included in the studies. A study including patients with
a primary UEDVT showed an increased risk while studies
including patients with secondary UEDVT did not show an
effect of oral contraceptives.
Surgery and plaster cast of the upper extremity result in stasis
in the upper extremity. Only one study investigated surgery and
plaster cast as a risk factor for UEDVT. This study found
surgery of the upper extremity as a risk factor with an odds
ratio of 13.1 (95% CI 2.1–80.6) [27]. Plaster cast of the arm
increased the risk, with an odds ratio of 7.0 (95% CI 1.7–29.5)
[27].
Other risk factors
Other possible risk factors for UEDVT are obesity, hormone
replacement therapy (HRT) and pregnancy. Few studies have
investigated these risk factors. Obesity and HRT were not risk
factors [27,53]. A case series reported pregnancy, especially in
combination with ovary hyperstimulation syndrome, as a risk
factor in women for UEDVT [54]. However, no large studies
were performed to assess the thrombotic risk for pregnancy.
Treatment
Unfortunately, no randomized controlled trials have been
performed on the optimal treatment for patients withUEDVT.
Therefore, there is still debate about what the best therapy is
and how side-effects can be minimized. Anticoagulation is the
most common treatment, with a similar strategy as for deep
vein thrombosis of the leg consisting of low molecular weight
heparin and vitamin K antagonists. Removal of the main risk
factor, for instance a CVC, probably reduces the risk of a
recurrent event. However, in most cases removal of the CVC is
not possible and therefore it is inserted in the other arm or on
the opposite side of the chest. Thrombolysis, surgery, thromb-
ectomy and balloon dilatation with and without stent placing
are used far less [55–59]. In these cases removal of a rib or
correction of malformations of the ribs or clavicle may be part
of the treatment. However, these aggressive forms of treatment
may have serious side-effects. Thrombolysis gives a higher risk
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of bleeding and surgery can cause pneumothorax, nerve
damage and rethrombosis [57,60]. Balloon thrombectomy
and venous stents can cause thrombosis by inducing intima
damage [59]. In several pilot studies thrombolysis was
compared with standard anticoagulation therapy in patients
with a UEDVT. Most patients reacted well to thrombolysis
and there were only a few more bleedings compared with the
standard treatment [61–63]. A clear advantage of thrombolytic
therapy has not been shown. Recently, the outcomes of the
RIETE registry of patients with venous thrombosis showed no
difference in outcome after 3 months of therapy in patients
with a deep vein thrombosis of the upper extremity or of the leg
[64]. However, in this study treatment for UEDVT was
different from that for thrombosis of the leg. Approximately
50% of the patients with UEDVT were only treated with low
molecular weight heparins for 3 months and the other half with
vitamin K antagonists. In venous thrombosis of the leg 70% of
patients were treated with vitamin K antagonists. Therefore,
the groups in this registry were not entirely comparable. These
results show that patients with UEDVT with their current
treatment have the same prognosis after 3 months as patients
with venous thrombosis of the leg. Whether this is the most
optimal treatment remains unclear.
Complications
The main complications of UEDVT are pulmonary emboli
(30%), post-thrombotic syndrome (PTS) and death [15,46,65–
67]. PTS occurs in 7–44% of patients [15,68,69] (Table 1).
These percentages are based on small studies with different
definitions of PTS. Mortality ranges from 15% to 50%, and is
high because of major co-morbidity (e.g. malignancy, infection
and multi-organ failure) [4,67,69].
In a few small studies the annual recurrence rate after a first
UEDVTwas 2% to 8%.However, groups were small and only
one study found thrombophilia to be a possible risk factor for a
recurrence; the other studies were too small to identify risk
factors [51,67,69].
Conclusion
UEDVT is a rare disease that mainly occurs in patients with a
CVC. Most other risk factors are the same as for patients with
a venous thrombosis of the leg. Mortality, pulmonary embo-
lism and PTS are the most important complications of
UEDVT but the incidences of these complications vary
between studies. The optimal treatment of UEDVT remains
unclear.
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